Top Markets
#1 Black Phoenix Black Phoenix +195.09%
#2 Islamic Coin Islamic Coin +158.04%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +36.39%
#5 Acurast Acurast +29.10%
#6 Cryptopia Cryptopia +21.79%
#7 BasedHype BasedHype +20.91%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +17.30%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#10 Playnance Playnance +14.07%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Classifica tra le azioni #90
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Prezzo delle azioni
$47.23
Capitalizzazione di mercato
$209.81B
Variazione (1 giorno)
-0.68%
Variazione (1 anno)
-7.63%
Paese
DK
Scambia Novo Nordisk A/S (NOVO-B)

Categoria

Healthcare
Utile per Novo Nordisk A/S (NOVO-B)
Utile nel Dec 2025 TTM: $20.51B
Secondo gli ultimi rapporti finanziari di Novo Nordisk A/S, gli utili attuali della società sono $20.51B. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Novo Nordisk A/S dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
$33.59B 63.83%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
$25.20B 22.88%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
$8.70B -57.58%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
$21.39B 4.31%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
$5.95B -70.99%
US